Diabetes, obesity & metabolism

Luseogliflozin added to Semaglutide in people with fatty liver disease linked to metabolism and type 2 diabetes: a randomized trial

Updated

Abstract

Antidiabetic therapy combining a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide-1 receptor agonist (GLP-1RA) is evaluated for its effects on liver histology in adults with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes.

  • Type 2 diabetes is linked to the worsening of metabolic dysfunction-associated steatohepatitis (MASH).
  • The study focuses on adults who have been confirmed to have MASH through biopsy.
  • Adding an SGLT2 inhibitor to GLP-1RA therapy may have a beneficial impact on liver tissue health.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free